• FirefoxInstall the new Firefox »
  •  Dow Up0.86% Nasdaq Up0.90%

    MediciNova Inc. (MNOV)

    3.54 0.00(0.00%) Mar 2, 3:35PM EST
    Add to Portfolio
    ProfileGet Profile for:
    MediciNova Inc.
    4275 Executive Square
    Suite 650
    La Jolla, CA 92037
    United States - Map
    Phone: 858-373-1500
    Fax: 858-404-0048
    Website: http://www.medicinova.com

    Index Membership:N/A
    Full Time Employees:11

    Business Summary 

    MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166, a anti-inflammatory and neuroprotective agent, which has completed Phase 2 clinical trials for the treatment of neurological disorders; MN-221, a ß2-adrenergic receptor agonist that has completed Phase 2b clinical trails for the treatment of acute exacerbations of asthma; MN-001, an orally bioavailable small molecule compound, which has completed Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; and MN-029, a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MediciNova Inc.

    Key Executives 
    Dr. Yuichi Iwaki M.D., Ph.D., 65
    Co-Founder, Chief Exec. Officer, Pres and Exec. Director
    Mr. Masatsune Okajima , 47
    Head of Japanese Office and VP
    Dr. Kazuko Matsuda M.D., Ph.D., MPH, 49
    Chief Medical Officer
    Ms. Esther van den Boom CPA,
    Chief Financial Officer
    Dr. Joji Suzuki M.D., Ph.D., 53
    Sr. VP of Fin. & Admin.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders